Screener
Veradermics MANE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | As of March 31, 2026 | As of December 31, 2025 |
|---|---|---|
| Common stock, $0.00001 par value, 200,000,000 and 267,466,797 shares authorized as of March 31, 2026 and December 31, 2025, respectively and 37,340,290 and 749,760 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 543,044 | 2,346 |
| Subscription receivable | (1,228) | — |
| Accumulated other comprehensive income | (524) | 60 |
| Accumulated deficit | (150,653) | (123,421) |
| Total stockholders’ equity (deficit) | 390,640 | (121,014) |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $397,356 | $152,619 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's total liabilities & equity?
- Veradermics (MANE) reported total liabilities & equity of $397.36M in Q1 2026.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Veradermics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude